Graves' disease - Associated changes in the serum lysosomal glycosidases activity and the glycosaminoglycan content

Clinica Chimica Acta

Volumn 331, Issue 1-2, 2003, Pages 97-102

  Komosińska Vassev, Katarzyna ^a   Olczyk, Krystyna ^a   Koźma, Ewa M ^a   Winsz Szczotka, Katarzyna ^a   Olczyk, Paweł ^a   Wisowski, Grzegorz ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Connective tissue; Graves' hyperthyroidism; Lysosomal enzymes; Oxidative stress

Indexed keywords

ALPHA FLUCOSIDASE; ALPHA MANNOSIDASE; ANTITHYROID AGENT; BETA DEXTRO XYLOSIDASE; BETA GALACTOSIDASE; BETA GLUCURONIDASE; GLYCOSAMINOGLYCAN; GLYCOSIDASE; HYDROLASE; N ACETYL BETA GLUCOSAMINIDASE; REACTIVE OXYGEN METABOLITE; THIAMAZOLE; UNCLASSIFIED DRUG; XYLAN 1,4 BETA XYLOSIDASE;

ADULT; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CARBOHYDRATE ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYMATIC DEGRADATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BLOOD LEVEL; EUTHYROIDISM; EXTRACELLULAR MATRIX; FEMALE; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; LYSOSOME; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

EID: 0037403185     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(03)00090-1     Document Type: Article

References (34)

1. Brix T.H., Kyvik K.O., Hegedüs L. What is the evidence of genetic factors in the etiology of Graves' disease? A brief review. Thyroid. 8:1998;627-634.
2. Costagliola S., Many M.C., Denef J.F., Pohlenz J., Refetoff S., Vassart G. Genetic immunization of outbred mice with thyrothropin receptor cDNA provides a model of Graves' disease. J. Clin. Invest. 105:2000;803-811.
3. Prydz K., Dalen K.T. Synthesis and sorting of proteoglycans. J. Cell. Sci. 113:2000;193-205.
4. Kjellen L., Lindahl U. Proteoglycans: structures and interactions. Annu. Rev. Biochem. 60:1991;443-475.
5. Selleck S.B. Proteoglycans and pattern formation. Suger biochemistry meets developmental genetics. TIG. 16:2000;206-212.
6. Kahaly G., Schuler M., Sewell C., Bernhard G., Beyer J., Krause U. Urinary glycosaminoglycans in Graves' ophthalmopathy. Clin. Endocrinol. 33:1990;35-44.
7. Kahaly G., Hansen C., Beyer J., Winand R. Plasma glycosaminonglycans in endocrine ophtalmopathy. J. Endocrinol. Invest. 17:1994;45-50.
8. Kahaly G., Förster G., Hansen K. Glycosaminoglycans in thyroid eye disease. Thyroid. 8:1998;429-432.
9. Wład H., Fenrych W., Ła̧cka K., Sikorska-Horst W. Urinary glycosaminoglycans in patients with hypothyroidism and in healthy subjects. J. Clin. Chem. Clin. Biochem. 26:1988;259-264.
10. Hansen C., Rouhi R., Forest G., Kahaly G.J. Increased sulfatation of orbital glycosaminoglycans in Graves' ophthalmopathy. J. Clin. Endocrinol. Metab. 84:1999;1409-1413.
11. Lu R., Wang P., Wartofsky L.et al. Oxygen free radicals in interleukin-1beta-induced glycosaminoglycan production by retroocular fibroblast from normal subjects and Graves' ophthalmopathy patients. Thyroid. 9:1999;297-303.
12. Wład H., Suszka B., Lła̧cka K., Chmiel J. Enzymes depolymerizing glycosaminoglycans in blood serum of patients with hyper and hypothyroidism. Endokrynol. Pol. 36:1985;215-220.
13. Guillou H., David V., Lorcy Y., Le Treut A., Allanic H., Le Gall J.-Y. Serum lysosomal acid hydrolase activities in Graves' disease. Clin. Chim. Acta. 120:1982;219-224.
14. Barrett A.J., Heath M.F. Lysosomal enzymes. Dingle J.T. Lysosomes: a laboratory handbook. 1977;19-147 Elsevier/North Holland Biomedical Press, Amsterdam.
15. Volpi N., Cusmano M., Venturelli T. Qualitative and quantitative studies of heparin and chondroitin sulfates in normal human plasma. Biochim. Biophys. Acta. 1243:1995;49-58.
16. Olczyk K., Głowacki A., Koźma E.M. Non-insulin-dependent diabetes mellitus-associated changes in serum glycosaminoglycans. Pathophysiology. 4:1997;121-129.
17. Blumenkrantz N., Asboe-Hansen G. New method for quantitative determination of uronic acids. Anal. Biochem. 54:1973;484-489.
18. Slim G.C., Furneaux R.H., Yorke S.C. A procedure for analysis of glycosaminoglycan mixtures based on digestion by specific enzymes. Carbohydr. Res. 255:1994;285-293.
19. Ullrich K., Gieselmann V., Mersmann G., von Figura K. Endocytosis of lysosomal enzymes by non-parenchymal rat liver cells. Comparative study of lysosomal enzymes uptake by hepatocytes and non-parenchymal liver cells. Biochem. J. 182:1979;329-335.
20. Pehowich D.J. Thyroid hormone status and membrane n-3 fatty acid content influence mitochondrial proton leak. Biochim. Biophys. Acta. 1411:1999;192-200.
21. Mano T., Sinohara R., Sawai Y.et al. Effects of thyroid hormone on coenzyme Q and other free radical scavengers in rat heart muscle. J. Endocrinol. 145:1995;131-136.
22. Venditti P., Di Meo S., De Leo T. Effect of thyroid state on characteristics determining the susceptibility to oxidative stress of mitochondrial fractions from rat liver. Cell. Physiol. Biochem. 6:1996;283-295.
23. Komosińska-Vassev K., Olczyk K., Kucharz E.J., Marcisz Cz., Winsz-Szczotka K., Kotulska A. Free radical activity and antioxidant defense mechanisms in patients with hyperthyroidism due to Graves' disease. Clin. Chim. Acta. 300:2000;107-117.
24. Glade M.J., Kanwar Y.S., Stern P.H. Insulin and thyroid hormones stimulate matrix metabolism in primary cultures of articular chondrocytes from young rabbits independently and in combination. Connect. Tissue Res. 31:1994;37-44.
25. Fries E., Blom A.M. Bikunin - not just a plasma proteinase inhibitor. Int. J. Biochem. Cell Biol. 32:2000;125-137.
26. Kresse H., Glössl J. Glycosaminoglycan degradation. Adv. Enzymol. 60:1987;217-311.
27. Frantzl-Zelman N., Hörandner H., Luegmayr E.et al. Effects of triiodothyronine on the morphology of cells and matrix, the localization of alkaline phosphatase, and the frequency of apoptosis in long-term cultures of MC3T3-E1 cells. Bone. 20:1997;225-236.
28. Smith T.J., Bahn R.S., Gorman C.A. Hormonal regulation of hyaluronate synthesis in cultured human fibroblasts: evidence for differences between retroocular and dermal fibroblasts. J. Clin. Endocrinol. Metab. 69:1989;1019-1023.
29. Yarman S., Gökkuşu C., Türkoǧlu Ü.M., Ademoǧlu E., Alagöl F. Urinary glycosaminoglycan levels in patients with Graves' ophtalmopathy: an effective parameter for the grading of ophtalmopathy. Med. Sci. Res. 24:1996;647-648.
30. Brown P.D., Giavazzi R. Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann. Oncol. 6:1995;967-974.
31. Fransson L.-A., Belting M., Edgren G.et al. Degradation and reprocessing of heparan sulphate in recycling glypican (heparan sulphate proteoglycan). Trends Glycosci. Glycotechnol. 10:1998;81-94.
32. Raats C.J., Bakker M.A., van den Born J., Berden J.H. Hydroxyl radicals depolymerize glomerular heparan sulfate in vitro and in experimental nephritic syndrome. J. Biol. Chem. 272:1997;26734-26741.
33. Fujimoto N., Mouri N., Iwata K., Ohuchi E., Okada Y., Hayakawa T. A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kDa gelatinase/type IV collagenase) using monoclonal antibodies. Clin. Chim. Acta. 30:1993;91-103.
34. Campo E., Merino M.J., Liotta L., Neumann R., Stetler-Stevenson W. Distribution of the 72-kd type IV collagenase in nonneoplastic thyroid tissue. Human Pathol. 23:1992;1395-1401.